<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ampicillin and sulbactam: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ampicillin and sulbactam: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ampicillin and sulbactam: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8745" href="/d/html/8745.html" rel="external">see "Ampicillin and sulbactam: Drug information"</a> and <a class="drug drug_patient" data-topicid="11290" href="/d/html/11290.html" rel="external">see "Ampicillin and sulbactam: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F135090"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Unasyn</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1045193"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Beta-lactam and Beta-lactamase Combination</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Penicillin</span></li></ul></div>
<div class="block don drugH1Div" id="F53462372"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosage recommendations are expressed as mg of the <b>ampicillin</b> component.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage forms information</b>
<b>:</b> Unasyn (ampicillin/sulbactam) is a combination product formulated in a 2:1 ratio (eg, each 3 g vial contains 2 g of ampicillin and 1 g of sulbactam); review dosing units carefully.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing (non-CNS), treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates: IV: 100 mg ampicillin/kg/day divided every 12 hours; dosing based on a pharmacokinetic analysis of 15 premature neonates using a 1:1 formulation of ampicillin to sulbactam (GA ≤28 weeks: n=6; GA &gt;28 weeks: n=9) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3025999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3025999'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates: IV: 100 mg ampicillin/kg/day divided every 8 hours; dosing based on a study in which 108 neonates (GA ≥37 weeks) received ampicillin/sulbactam in combination with amikacin for 3 to 8 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19297276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19297276'])">Ref</a></span>). <b>Note:</b> Higher dosing may be necessary for severe/resistant infections (eg, resistant <i>Acinetobacter baumannii</i>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31992156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31992156'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F135104"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosage recommendations are expressed as mg of the <b>ampicillin</b> component.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage forms information</b>
<b>:</b> Unasyn (ampicillin/sulbactam) is a combination product formulated in a 2:1 ratio (eg, each 3 g vial contains 2 g of ampicillin and 1 g of sulbactam); review dosing units carefully.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate infection: Infants, Children, and Adolescents: IV, IM: 100 to 200 mg ampicillin/kg/day divided every 6 hours; usual maximum dose: 2,000 mg ampicillin/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2022','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2022','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe infection (eg, meningitis, resistant <i>Streptococcus pneumoniae</i>): Infants, Children, and Adolescents: IV: 200 to 400 mg ampicillin/kg/day divided every 6 hours; usual maximum dose: 2,000 mg ampicillin/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>). <b>Note:</b> Higher dosing and alternative dosing strategies (eg, extended infusions, continuous infusions) have also been used to treat <i>Acinetobacter baumannii</i> infections in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34864936','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34864936','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment:</b> Limited data available: Children and Adolescents: IV: 200 to 300 mg ampicillin/kg/day divided every 4 to 6 hours; maximum dose: 2,000 mg ampicillin/dose. Recommended combination therapy and duration vary by causative pathogen; treatment duration is at least 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5252d319-da98-4b4d-a87f-8cfa2f63afe8">Intra-abdominal infection, complicated, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated, treatment:</b>
<b>Note:</b> Not recommended for empiric treatment due to high rates of <i>Escherichia coli</i> resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-28085573'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 200 mg ampicillin/kg/day divided every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea65a8b1-e322-4417-b372-ae2b2b3d970d">Meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis:</b> Limited data available: <b>Note:</b> Experience is limited; not included in IDSA meningitis guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 400 mg ampicillin/kg/day in divided doses every 4 to 6 hours; maximum dose: 2,000 mg ampicillin/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3025997','lexi-content-ref-8249199','lexi-content-ref-AAP.1','lexi-content-ref-3026015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3025997','lexi-content-ref-8249199','lexi-content-ref-AAP.1','lexi-content-ref-3026015'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e01e9053-4cab-43d5-982b-2eaac05c1b5a">Osteoarticular infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoarticular infection:</b> Limited data available: Infants, Children, and Adolescents: IV: 200 mg ampicillin/kg/day in divided doses every 6 hours; maximum dose: 2,000 mg ampicillin/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3026018','lexi-content-ref-8249199','lexi-content-ref-2677956','lexi-content-ref-28708801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3026018','lexi-content-ref-8249199','lexi-content-ref-2677956','lexi-content-ref-28708801'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19ad33d2-38a3-4047-a6e2-816347270335">Pelvic inflammatory disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic inflammatory disease (alternative agent):</b> Adolescents: IV: 2,000 mg ampicillin every 6 hours in combination with doxycycline. After 24 to 48 hours of sustained clinical improvement, may transition to oral therapy to complete 14 days of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f8304f63-519f-4407-938f-823fc40f97fa">Rhinosinusitis, severe infection requiring hospitalization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, severe infection requiring hospitalization:</b> Limited data available: Children and Adolescents: IV: 200 to 400 mg ampicillin/kg/day divided every 6 hours for 10 to 14 days; maximum dose: 2,000 mg ampicillin/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b> Children and Adolescents: IV: 200 mg ampicillin/kg/day divided every 6 hours for up to 14 days; maximum dose: 2,000 mg ampicillin/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Limited data available: Children and Adolescents: IV: 50 mg ampicillin/kg/<b>dose</b> within 60 minutes prior to procedure; may repeat in 2 hours if lengthy procedure or excessive blood loss; maximum dose: 2,000 mg ampicillin/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51064835"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 29 mL/minute/1.73 m<sup>2</sup>: Administer every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 5 to 14 mL/minute/1.73 m<sup>2</sup>: Administer every 24 hours.</p></div>
<div class="block dohp drugH1Div" id="F51064836"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F135094"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8745" href="/d/html/8745.html" rel="external">see "Ampicillin and sulbactam: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Adult dosage recommendations are expressed as total grams of ampicillin/sulbactam.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage forms information:</b> Ampicillin/sulbactam is a combination product formulated in a 2:1 ratio.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b>
<b>IM, IV:</b> 1.5 to 3 g every 6 hours (maximum: ampicillin/sulbactam 12 g daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); for the treatment of infections caused by <i>Acinetobacter</i> spp., higher doses have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30882373','lexi-content-ref-33318006','lexi-content-ref-18501431','lexi-content-ref-18197724','lexi-content-ref-23710070','lexi-content-ref-34864936','lexi-content-ref-12507838','lexi-content-ref-29531445','lexi-content-ref-31011353']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30882373','lexi-content-ref-33318006','lexi-content-ref-18501431','lexi-content-ref-18197724','lexi-content-ref-23710070','lexi-content-ref-34864936','lexi-content-ref-12507838','lexi-content-ref-29531445','lexi-content-ref-31011353'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="83e0ebe8-b935-4f5a-a26d-c059d314bdfc">
<i>Acinetobacter baumannii</i> infection, multidrug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>
<i>Acinetobacter baumannii</i> infection, multidrug-resistant: IV: </b>9 g every 8 hours over 4 hours <b>or</b> 27 g/day over 24 hours as a continuous infusion; may treat mild infections with 3 g every 4 hours, especially if intolerance or toxicity precludes the use of higher doses. Use as part of an appropriate combination regimen in moderate to severe infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30882373','lexi-content-ref-33318006','lexi-content-ref-18501431','lexi-content-ref-23710070','lexi-content-ref-34864936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30882373','lexi-content-ref-33318006','lexi-content-ref-18501431','lexi-content-ref-23710070','lexi-content-ref-34864936'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b74db564-f66e-4f55-8b58-9759dc214a0c">Bite wound infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, treatment (animal or human bite) (off-label use):</b>
<b>IV:</b> 1.5 to 3 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>); some experts prefer 3 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2021a','lexi-content-ref-Baddour.2021b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2021a','lexi-content-ref-Baddour.2021b'])">Ref</a></span>). Duration of treatment for established infection is typically 5 to 14 days (including oral step-down therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2021a','lexi-content-ref-Baddour.2021b','lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2021a','lexi-content-ref-Baddour.2021b','lexi-content-ref-24973422'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection (off-label use):</b>
<i>For pathogen-directed therapy of susceptible organisms:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 3 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710','lexi-content-ref-11213849','lexi-content-ref-Murray.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710','lexi-content-ref-11213849','lexi-content-ref-Murray.2019'])">Ref</a></span>). Usual duration is 7 to 14 days; individualize depending on organism, source of infection, and clinical response. A 7-day duration is recommended for patients with uncomplicated Enterobacteriaceae infection who respond appropriately to antibiotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanafani.2019','lexi-content-ref-Moehring.2019','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanafani.2019','lexi-content-ref-Moehring.2019','lexi-content-ref-30535100'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d3e4522-e8bc-4496-b3e0-f1fcdd0f13d7">Diabetic foot infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection, moderate to severe:</b>
<b>IV:</b> 3 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15865549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15865549'])">Ref</a></span>). Usual duration of therapy (including oral step-down therapy) is 2 to 4 weeks (in the absence of osteomyelitis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15865549','lexi-content-ref-22619242','lexi-content-ref-Weintrob.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15865549','lexi-content-ref-22619242','lexi-content-ref-Weintrob.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment (off-label use):</b>
<i>Enterococcus (native or prosthetic valve; beta-lactamase–producing strains susceptible to aminoglycosides):</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 3 g every 6 hours in combination with gentamicin for 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d31b3c05-03cb-4fcd-8932-e9d1953c0ab8">Odontogenic soft tissue infection, pyogenic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Odontogenic soft tissue infection, pyogenic (off-label use):</b>
<b>IV:</b> 3 g every 6 hours; following clinical improvement, transition to oral step-down therapy and continue antibiotics until resolution, typically for a total of 7 to 14 days. Use in addition to appropriate surgical management (eg, drainage and/or extraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21370eae-9503-4220-8a5d-00bdd78d879e">Pelvic infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic infections (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intra-amniotic infection (chorioamnionitis):</i>
<b>IV:</b> 3 g every 6 hours. Continue until vaginal delivery or for 1 dose after cesarean delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28742677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28742677'])">Ref</a></span>). <b>Note:</b> Some experts recommend 1 additional dose after vaginal delivery and extension of antibiotics after cesarean delivery until patient is afebrile and asymptomatic ≥48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tita2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tita2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pelvic inflammatory disease (including tubo-ovarian abscess) (alternative agent):</i>
<b>IV:</b> 3 g every 6 hours in combination with doxycycline. After 24 to 48 hours of sustained clinical improvement, may transition to oral therapy to complete 14 days of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postpartum endometritis:</i>
<b>IV:</b> 3 g every 6 hours; treat until patient is clinically improved (no fundal tenderness) and afebrile for 24 to 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chen.2019','lexi-content-ref-8866384']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chen.2019','lexi-content-ref-8866384'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2f0164e-28ab-4d30-b893-da899a8afeac">Peritonitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis, treatment (peritoneal dialysis patients):</b> Pathogen-directed therapy for susceptible organisms. <b>Note:</b> Intraperitoneal administration is preferred to IV administration. Duration of therapy is ≥2 weeks for patients with adequate clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Burkart.2019','lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Burkart.2019','lexi-content-ref-27282851'])">Ref</a></span>). Consider a 25% dose increase in patients with significant residual renal function (urine output &gt;100 mL/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851','lexi-content-ref-20628102','lexi-content-ref-29987068','lexi-content-ref-29987069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851','lexi-content-ref-20628102','lexi-content-ref-29987068','lexi-content-ref-29987069'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent (preferred):</i>
<b>Intraperitoneal:</b> 3 g per exchange every 12 hours; allow to dwell for ≥6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2099158','lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2099158','lexi-content-ref-27282851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous (with every exchange) (dose is per liter of dialysate):</i>
<b>Intraperitoneal:</b> Loading dose: 750 mg/<b>L</b> to 1 g/<b>L</b> of dialysate with first exchange of dialysate; maintenance dose: 100 mg/<b>L</b> of dialysate with each subsequent exchange (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851','lexi-content-ref-18708550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851','lexi-content-ref-18708550'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Aspiration pneumonia, community-acquired (nonsevere):</i>
<b>IV:</b> 1.5 to 3 g every 6 hours, generally for 5 days (including oral step-down therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Klompas.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Klompas.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Community-acquired pneumonia: </i>Inpatients without risk factors for<i> P. aeruginosa:</i>
<b>IV:</b> 3 g every 6 hours in combination with other agent(s) when appropriate. Total duration (including oral step-down therapy) is a minimum of 5 days; patients should be clinically stable with normal vital signs prior to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350','lexi-content-ref-23904004','lexi-content-ref-Rossoff.1995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350','lexi-content-ref-23904004','lexi-content-ref-Rossoff.1995'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hospital-acquired or ventilator-associated pneumonia:</i>
<b>IV:</b> 3 g every 6 hours, as part of a combination regimen when appropriate. Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20837632','lexi-content-ref-27521441','lexi-content-ref-27496018','lexi-content-ref-24263165']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20837632','lexi-content-ref-27521441','lexi-content-ref-27496018','lexi-content-ref-24263165'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis (off-label use):</b>
<b>IV:</b> 3 g within 60 minutes prior to surgical incision. Doses may be repeated in 2 hours if procedure is lengthy or if there is excessive blood loss. <b>Note:</b> Consider local susceptibility patterns prior to use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Anderson.2019','lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Anderson.2019','lexi-content-ref-23327981'])">Ref</a></span>). In cases in which extension of prophylaxis is warranted postoperatively, total duration should be ≤24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Anderson.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Anderson.2019'])">Ref</a></span>). Postoperative prophylaxis is not recommended in clean and clean-contaminated surgeries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28467526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28467526'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b86aa8e-9c80-4250-bfe7-202ab443aa9d">Surgical site infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical site infection (eg, intestinal, GU tract, abdominal wall) (off-label use):</b>
<b>IV:</b> 3 g every 6 hours. Duration depends on extent and severity of infection as well as response to therapy; may switch to oral treatment when clinically improved. <b>Note:</b> Consult local susceptibility patterns prior to empiric use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Mancino.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Mancino.2019'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991106"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Renally adjusted dose recommendations are based on a usual recommended dose of 1.5 to 3 g every 6 hours and are expressed as total grams of ampicillin/sulbactam.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function</b>: <b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Estimation of renal function for the purpose of drug dosing should be done using the Cockcroft-Gault formula. Dosage recommendations are expressed as grams of <b>ampicillin/sulbactam</b> combination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6309731','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6309731','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 29 mL/minute: 1.5 to 3 g every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 5 to 14 mL/minute: 1.5 to 3 g every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically-ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.5 to 3 g every 4 to 6 hours (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (39% to 63%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4345622']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4345622'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.5 to 3 g every 12 to 24 hours; administer after dialysis when scheduled dose falls on dialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: IV: </b>1.5 g every 12 hours or 3 g every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2099158','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2099158','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: <b>IV: </b>3 g every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 3 g followed by 1.5 to 3 g every 8 to 12 hours. Where possible, give one dose after PIRRT session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22223613','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22223613','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988407"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There is no dosage adjustment provided in the manufacturer’s labeling. </p></div>
<div class="block adr drugH1Div" id="F135061"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see Ampicillin.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Local: Pain at injection site (IM: 16%; IV: 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Phlebitis (1%), thrombophlebitis (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, edema, substernal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, facial swelling, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, flatulence, glossitis, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytosis (atypical), mucous membrane bleeding</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, fatigue, headache, malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Constriction of the pharynx, epistaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin, decreased serum total protein, increased lactate dehydrogenase</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Casts in urine (hyaline), finding of blood in urine</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Basophilia, decreased hematocrit, decreased hemoglobin, decreased neutrophils, decreased red blood cells, eosinophilia, leukopenia, lymphocytopenia, monocytosis, thrombocythemia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, cholestasis, <i>Clostridioides difficile</i> associated diarrhea, dyspepsia, gastritis, hairy tongue, melena, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, hemolytic anemia, immune thrombocytopenia, positive direct Coombs test</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis, cholestatic jaundice, hepatitis, hyperbilirubinemia, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p></div>
<div class="block coi drugH1Div" id="F135077"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylaxis or Stevens-Johnson syndrome) to ampicillin, sulbactam, or to other beta-lactam antibacterial drugs (eg, penicillins, cephalosporins), or any component of the formulations; history of cholestatic jaundice or hepatic dysfunction associated with ampicillin/sulbactam</p></div>
<div class="block war drugH1Div" id="F135058"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity or a history of sensitivity to multiple allergens. Patients with a history of penicillin hypersensitivity have experienced severe reactions when treated with cephalosporins. Before initiating therapy, carefully investigate previous penicillin, cephalosporin, or other allergen hypersensitivity. If an allergic reaction occurs, discontinue and institute appropriate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hepatic dysfunction: Hepatitis and cholestatic jaundice have been reported (including fatalities). Toxicity is usually reversible. Monitor hepatic function at regular intervals in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Rash: Appearance of a rash should be carefully evaluated to differentiate a nonallergic ampicillin rash from a hypersensitivity reaction; rash occurs in 5% to 10% of children and is a generalized dull red, maculopapular rash, generally appearing 3-14 days after the start of therapy. It normally begins on the trunk and spreads over most of the body. It may be most intense at pressure areas, elbows, and knees.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hepatic impairment: Hepatotoxicity has been reported. Monitor hepatic function at regular intervals in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Infectious mononucleosis: A high percentage of patients with infectious mononucleosis have developed rash during therapy; ampicillin-class antibacterials are not recommended in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p></div>
<div class="block foc drugH1Div" id="F135070"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unasyn: 3 g: Ampicillin 2 g and sulbactam 1 g (1 ea); 1.5 g: Ampicillin 1 g and sulbactam 0.5 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.5 g: Ampicillin 1 g and sulbactam 0.5 g (1 ea); 3 g: Ampicillin 2 g and sulbactam 1 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 g: Ampicillin 10 g and sulbactam 5 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unasyn: 15 g: Ampicillin 10 g and sulbactam 5 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.5 g: Ampicillin 1 g and sulbactam 0.5 g (1 ea); 15 g: Ampicillin 10 g and sulbactam 5 g (1 ea); 3 g: Ampicillin 2 g and sulbactam 1 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F135054"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322990"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Ampicillin-Sulbactam Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 (1-0.5) g (per each): $3.25 - $9.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 (2-1) g (per each): $3.84 - $19.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Ampicillin-Sulbactam Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 (1-0.5) g (per each): $6.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 (2-1) g (per each): $11.08 - $11.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 (10-5) g (per each): $37.80 - $90.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Unasyn Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 (1-0.5) g (per each): $9.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 (2-1) g (per each): $17.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Unasyn Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 (10-5) g (per each): $87.37</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612236"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer by deep IM injection.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer by slow IV injection over 10 to 15 minutes or by intermittent IV infusion over 15 to 30 minutes. Avoid infusing concomitantly with aminoglycosides if feasible; consult drug interactions database for more information.</p></div>
<div class="block adm drugH1Div" id="F135074"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer around-the-clock to promote less variation in peak and trough serum levels.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer by slow injection over 10 to 15 minutes or as an IV infusion over 15 to 30 minutes. For some indications (eg, <i>Acinetobacter</i> infections), total daily dose may be administered over 24 hours as a continuous infusion (Beganovic 2021; IDSA [Tamma 2022]). Ampicillin and gentamicin should not be mixed in the same IV tubing.</p>
<p style="text-indent:-2em;margin-left:2em;">Some penicillins (eg, ampicillin, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides <i>in vitro</i>. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent Y-site administration should be avoided.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>IM:</b> Inject deep IM into large muscle mass; a concentration of 375 mg/mL ampicillin/sulbactam (250 mg ampicillin/125 mg sulbactam per mL) is recommended; may be diluted in sterile water or lidocaine 0.5% or lidocaine 2% for IM administration.</p></div>
<div class="block sts drugH1Div" id="F135084"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to reconstitution, store at 20°C to 25°C (68°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Concentration of 375 mg/mL (250 mg ampicillin/125 mg sulbactam) should be used within 1 hour after reconstitution.</p>
<p style="text-indent:-2em;margin-left:2em;">Intermittent IV infusion: Refer to manufacturer's labeling for specific storage instructions after reconstitution and dilution (varies by concentration and diluent).</p></div>
<div class="block usep drugH1Div" id="F53565428"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of skin and soft tissue infections (FDA approved in ages ≥1 year and adults); treatment of intra-abdominal and gynecological infections (FDA approved in adults); has also been used for treatment of endocarditis, meningitis, and osteoarticular infection, and for surgical prophylaxis.</p></div>
<div class="block cyt drugH1Div" id="F13298749"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F135063"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Ampicillin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atenolol: Ampicillin may decrease the bioavailability of Atenolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: May decrease the serum concentration of Ampicillin. Management: Separate the administration of ampicillin and chloroquine by at least 2 hours to minimize any potential negative impact of chloroquine on ampicillin bioavailability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Khat: May decrease the serum concentration of Ampicillin. Management: Consider administering ampicillin 2 hours after khat chewing to avoid reductions in ampicillin bioavailability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Ampicillin. Management: Administer oral ampicillin at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Sulbactam. Management: Recommendations for management of this interaction vary by specific sulbactam-containing product. Coadministration of probenecid with sulbactam/durlobactam is not recommended, but no specific actions are recommended for ampicillin/sulbactam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegoprazan: May decrease the serum concentration of Ampicillin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F135079"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F6028245"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Both ampicillin and sulbactam cross the placenta (Foulds 1986; Maberry 1992).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of ampicillin/sulbactam may be altered (Chamberlain 1993; Foulds 1986).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, penicillin antibiotics are widely used in pregnant patients. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Lamont 2014; Muanda 2017a; Muanda 2017b).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated intra-amniotic infection (chorioamnionitis) may lead to adverse pregnancy outcomes (including pneumonia, meningitis, and sepsis) in the newborn. Maternal complications may include postpartum uterine atony with hemorrhage, endometritis, peritonitis, sepsis, or adult respiratory distress syndrome. Ampicillin/sulbactam is an alternative option for the treatment of intra-amniotic infection (ACOG 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Antibiotic prophylaxis is recommended prior to all cesarean deliveries unless the patient is already receiving an appropriate antibiotic. A single dose of a targeted antibiotic administered within 60 minutes prior to the delivery is recommended; ampicillin/sulbactam has been evaluated for this purpose, although other antibiotics may be preferred (consult current recommendations) (ACOG 2018).</p></div>
<div class="block mopp drugH1Div" id="F53565425"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">SCr; CBC (with prolonged therapy), LFTs (with prolonged therapy or in patients with preexisting hepatic impairment). Observe for change in bowel frequency; monitor for signs of anaphylaxis during first dose.</p></div>
<div class="block pha drugH1Div" id="F135057"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. The addition of sulbactam, a beta-lactamase inhibitor, to ampicillin extends the spectrum of ampicillin to include some beta-lactamase-producing organisms.</p></div>
<div class="block phk drugH1Div" id="F135076"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ampicillin:</b> See Ampicillin monograph.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sulbactam:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Distribution: Widely distributed to bile, blister, and tissue fluids; poor penetration into CSF with uninflamed meninges; higher concentrations attained with inflamed meninges.</p>
<p style="text-indent:-2em;margin-left:6em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≤12 years: 0.34 ± 0.12 L/kg (Nahata 1999).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: 0.36 L/kg (Foulds 1986).</p>
<p style="text-indent:-2em;margin-left:4em;">Protein binding: 38%.</p>
<p style="text-indent:-2em;margin-left:4em;">Half-life elimination: Children ≤12 years (normal renal function): Mean: 0.81 ± 0.12 hours (Nahata 1999); Adults (normal renal function): 1 to 1.3 hours; <b>Note:</b> Elimination kinetics of both ampicillin and sulbactam are similarly affected in patients with renal impairment, therefore, the blood concentration ratio is expected to remain constant regardless of renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">Excretion: Urine (~75% to 85% as unchanged drug) within 8 hours.</p></div>
<div class="block phksp drugH1Div" id="F56053430"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Ampicillin: See Ampicillin monograph.</p>
<p style="text-indent:-2em;margin-left:6em;">Sulbactam (in combination with ampicillin):</p>
<p style="text-indent:-2em;margin-left:8em;">Time dependent; associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC):</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Acinetobacter baumannii:</i> Goal: ≥40% to 60% <i>f</i>T &gt; MIC (bactericidal) (Yokoyama 2014; Yokoyama 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug exposure in patients with normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≤12 years of age: C<sub>max </sub>(peak): IV:</p>
<p style="text-indent:-2em;margin-left:8em;">15- to 40-minute infusion, steady state: Ampicillin 26.7 to 53.3 mg/kg/dose and sulbactam 13.3 to 26.7 mg/kg/dose every 6 hours: Ampicillin: 177 to 200 mg/L; sulbactam: 81.9 to 102 mg/L (Nahata 1999).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: C<sub>max</sub> (peak):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Adult doses are expressed as the combined amount of ampicillin and sulbactam.</p>
<p style="text-indent:-2em;margin-left:8em;">IV: 15-minute infusion, single dose:</p>
<p style="text-indent:-2em;margin-left:10em;">1.5 g: Ampicillin: 40 to 71 mg/L; sulbactam: 21 to 40 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">3 g: Ampicillin: 109 to 150 mg/L; sulbactam: 48 to 88 mg/L.</p>
<p style="text-indent:-2em;margin-left:8em;">IM:</p>
<p style="text-indent:-2em;margin-left:10em;">1.5 g: Ampicillin: 8 to 37 mg/L; sulbactam: 6 to 24 mg/L.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038527"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Unasyn</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aminoxidin sulbactam | Ampicilina sulbactam norgreen | Ampicilina sulbactam pharmavial | Ampigen sb | Decilina compuesta | Prixin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ampicillin/Sulbactam AptaPharma | Ampicillin/sulbactam astro | Unasyn</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ampisulcillin | Unasyn</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ampicilina sodica + sulbactam sodica | Ampicilina sodica + sulbactam sodico | Libractan | Sulbacter | Unasyn</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ampicilina+sulbactam | Unasyna</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ampicillin sodium and sulbactam sodium | Ampicillin/sulbact | An te xian | Bei shu lin | Betamp | Er ye qiang | Er ye shu | Hai fu bo | Jia sai | Kai de lin | Kai lan xin | Lai qie li | Li an lin | Li tan | Pu shu | Qi sa | Qing tan wei | Rui an da | Shu an xin | Shu jia qing | Shu li wei | Shu sa lin | Shu ta bi tuo | Sulbactam/ampicil | Tian shu xin | Unasyn | Wei an xin | Xi di lin | Xin an lin | You pu lin | Zhen pai</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">AMPICILINA + SULBACTAM | Ampicilina sulbactam | Ampicilina y Sulbactam | Ampicilina+sulbactam | Ampidelt | Amplisul | Auropennz | Biosabactam | Fipexiam | Sulamp | Sulbactam + ampicilina | Sulpitam | Sultamicilina | Unasyn | Xilbac</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ampicillin and Sulbactam IBI | Bitammon | Unasyn</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ampicillin + Sulbactam DeltaSelect | Ampicillin comp | Ampicillin plus sulbactam eberth | Ampicillin Sulb. Teva | Ampicillin und Sulbactam IBI | Ampicillin/Sulbactam Actavis | Ampicillin/sulbactam aurobindo | Ampicillin/Sulbactam Kabi | Ampicillin/sulbactam puren | Unacid</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ampibactam | Fipexiam | Unasyn</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ampicilina sulbactam | Ampicilina y Sulbactam | Ampicilina+sulbactam | Ampicilina/sulbactam biosano | Amplisul | Sulbam | Sultamix | Unasyn | Xilbac</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Alfasid | Ampicillin &amp; sulbactam | Ampisulcillin | Unasyn</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ampictam | Sabect | Sulbin | Synerpen | Ultracillin | Unasyn | Unictam</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Unasyn</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Ampicillin and sulbactam | Ampicillin/sulbactam | Sulbactam/ampicillin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Unacim</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dicapen | Unasyn</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Begalin p | Demotine</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Kintamvy | Unasyn</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ampicillin/Sulbactam AptaPharma | Unasyn</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bactesyn | Cinam | Picyn | Unasyn | Viccillin SX</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ampifect s | Ampirok | Ampitum | Cinclox s | Saltum | Sulbacin | Sulbact</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ampicill+Sulb ibi | Bethacil</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Unasyn</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Picillibacta | Pisulcin | Sulbac Ampicil | Sulbacsin | Unasyn s | Yucion-s | Yunasupin | Yunasupin chemix</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Mahacillin s | Sulbacin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aerbactam | Ambactam | Ampibactam | Ampitam | Baccillin | Bactacin | Bactamcillin | Lactacillin | Projin | Rukasyn | Ssulbacin | Sulbacillin | Sulbacin | Sulin | Sultam | Synertam | Ubacillin | Ubacsin | Ubactam | Ucilin | Ucillin | Unasyn | Unisulam | Uposin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ampicillin &amp; sulbactam | Ampicillin/sulbactam | Ampiplus | Ampisulcillin | Bestpen s | Bitammon | Unasyn</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ampisid | Sulbacin | Unasyn</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Unasyne</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Unasyna</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ampicillin+sulbactam | Auropennz | Sulbacin | Sulbamp | Unasyn</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Unasyn</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ampicillin plus sulbactam eberth</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">AMPICILINA + SULBACTAM | Ampisulkem | Fipexiam | Unasyn</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ambacitam | Ampibax | Ampicare | Ampico Sbt | Ampimax | Ampisul | Ampisultam | Amsucillin | Amsulvex | Amsutas | Bactacin | Biocillin plus | Ciltamin | Disulbac | Duobaclin | Gravitam | Linsul | Miasyn | Qualisultam | Sentram | Silgram | Sulbacin | Sultacillin | Sybactam | Unasan | Unasyn | Unathix | Unsin | Zulbactam</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ambac | Ampitam | Sulbacin | Unasyn</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ultraproct | Unasyn</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ampicillin and sulbactam | Unasyn</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aminoxidin sulbactam | Ampicilina sulbactam eticos | Ampicilina sulbactam gemepe | Ampicilina sulbactam interlabo | Ampicilina sulbactam nortelab | Ampicilina sulbactam vivele | Cilimpil bactam | Klafen | Libractam | Norake ibl</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Unasyn</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Amibactam | Ampicillin sulbactam | Ampicillin+sulbactam | Ampisid | Complisan | Libakcil | Sulacillin | Sulbacin | Sultasin | Unasyn</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ampiplus | Unasyn</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ampicilin/sulbaktam aptapharma | Penactam | Unasyn</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ampisulcillin | Bitammon | Unasyn</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ambacitam | Ampitam | Amsubac | Sulam | Sulbaccin | Unasyn</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Devasid | Duobak | Duobaktam | Nobecid | Sulbaksit | Sultasid | Sultibac</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ambacillin | Amsulber cyh | Ansullina | Subacillin | Sulampi | Unasyn</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ampicillin+sulbactam | Ampisid | Ampisulbin | Ampisulcillin | Unasyn</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aminoxidin sulbactam | Ampicilina sulbactam | Ampisul | Libractam | Maxicilina Sulbactam | Sulbampicin 1500 a+s | Sulbampicin 3000 a+s | Unasyn</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ampibactan | AMPICILINA + SULBACTAM | Ampicilina sulbactam | Ampicilina+sulbactam | Ampidelt | Ampilab | Ampitren | Ampiwell s | Amtacilyn | Fipexiam | Sentram | Sinif | Sulamp | Sulpexium | Sultamilan | Unacilyn | Unasyn</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Ama power | Auropennz</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Sulbacin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27891788">
<a name="27891788"></a>Ailes EC, Gilboa SM, Gill SK, et al; The National Birth Defects Prevention Study. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol</i>. 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett E, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28742677">
<a name="28742677"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion No. 712: Intrapartum management of intraamniotic infection. <i>Obstet Gynecol</i>. 2017;130(2):e95-e101. doi:10.1097/AOG.0000000000002236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/28742677/pubmed" id="28742677" target="_blank">28742677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30134425">
<a name="30134425"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: Use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol</i>. 2018;132(3):e103-e119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/30134425/pubmed" id="30134425" target="_blank">30134425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Anderson.2019">
<a name="Anderson.2019"></a>Anderson DJ, Sexton DJ. Overview of control measures for prevention of surgical site infection in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3026018">
<a name="3026018"></a>Aronoff SC, Scoles PV, Makley JT, Jacobs MR, Blumer JL, Kalamchi A. Efficacy and safety of sequential treatment with parenteral sulbactam/ampicillin and oral sultamicillin for skeletal infections in children. <i>Rev Infect Dis</i>. 1986;8(suppl 5):S639-S643. doi:10.1093/clinids/8.supplement_5.s639<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/3026018/pubmed" id="3026018" target="_blank">3026018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30882373">
<a name="30882373"></a>Assimakopoulos SF, Karamouzos V, Lefkaditi A, et al. Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant <i>Acinetobacter baumannii</i>: a case series study. <i>Infez Med</i>. 2019;27(1):11-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/30882373/pubmed" id="30882373" target="_blank">30882373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2021a">
<a name="Baddour.2021a"></a>Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 20, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2021b">
<a name="Baddour.2021b"></a>Baddour LM, Harper M. Human bites: evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373316">
<a name="26373316"></a>Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/26373316/pubmed" id="26373316" target="_blank">26373316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Beigi.2019">
<a name="Beigi.2019"></a>Beigi RH. Management and complications of tubo-ovarian abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33318006">
<a name="33318006"></a>Beganovic M, Daffinee KE, Luther MK, LaPlante KL. Minocycline alone and in combination with polymyxin b, meropenem, and sulbactam against carbapenem-susceptible and -resistant <i>Acinetobacter baumannii</i> in an <i>in vitro</i> pharmacodynamic model. <i>Antimicrob Agents Chemother</i>. 2021;65(3):e01680-20. doi:10.1128/AAC.01680-20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/33318006/pubmed" id="33318006" target="_blank">33318006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28467526">
<a name="28467526"></a>Berríos-Torres SI, Umscheid CA, Bratzler DW, et al; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017 [published correction appears in <i>JAMA Surg</i>. 2017;152(8):803]. <i>JAMA Surg</i>. 2017;152(8):784-791. doi:10.1001/jamasurg.2017.0904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/28467526/pubmed" id="28467526" target="_blank">28467526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18501431">
<a name="18501431"></a>Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant <i>Acinetobacter baumannii</i> ventilator-associated pneumonia.<i> J Infect</i>. 2008;56(6):432-436. doi:10.1016/j.jinf.2008.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/18501431/pubmed" id="18501431" target="_blank">18501431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2099158">
<a name="2099158"></a>Blackwell BG, Leggett JE, Johnson CA, Zimmerman SW, Craig WA. Ampicillin and sulbactam pharmacokinetics and pharmacodynamics in continuous ambulatory peritoneal dialysis (CAPD). <i>Perit Dial Int.</i> 1990;10(3):221-226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/2099158/pubmed" id="2099158" target="_blank">2099158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015 ;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2022">
<a name="Bradley.2022"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Diseases Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm.</i> 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burkart.2019">
<a name="Burkart.2019"></a>Burkart JM. Microbiology and therapy of peritonitis in peritoneal dialysis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chamberlain.1993">
<a name="Chamberlain.1993"></a>Chamberlain A, White S, Bawdon R, Thomas S, Larsen B. Pharmacokinetics of ampicillin and sulbactam in pregnancy. <i>Am J Obstet Gynecol</i>. 1993;168(2):667-673.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20837632">
<a name="20837632"></a>Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant <i>Acinetobacter baumannii</i> ventilator-associated pneumonia. <i>J Intensive Care Med</i>. 2010;25(6):343-348. doi:10.1177/0885066610377975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/20837632/pubmed" id="20837632" target="_blank">20837632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chen.2019">
<a name="Chen.2019"></a>Chen KT. Postpartum endometritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chow.2019">
<a name="Chow.2019"></a>Chow AW. Complications, diagnosis, and treatment of odontogenic infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis.</i> 2012;54(8):e72-e112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8783704">
<a name="8783704"></a>Cisneros JM, Reyes MJ, Pachón J, et al. Bacteremia due to <i>Acinetobacter baumannii</i>: epidemiology, clinical findings, and prognostic features. <i>Clin Infect Dis</i>. 1996;22(6):1026-1032. doi:10.1093/clinids/22.6.1026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/8783704/pubmed" id="8783704" target="_blank">8783704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med</i>. 2009 ;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31260651">
<a name="31260651"></a>Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. <i>Am J Obstet Gynecol</i>. 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/31260651/pubmed" id="31260651" target="_blank">31260651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3025997">
<a name="3025997"></a>Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. <i>Rev Infect Dis.</i> 1986;8(suppl 5):S503-S510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/3025997/pubmed" id="3025997" target="_blank">3025997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8866384">
<a name="8866384"></a>Gall S, Koukol DH. Ampicillin/sulbactam vs. clindamycin/gentamicin in the treatment of postpartum endometritis. <i>J Reprod Med</i>. 1996;41(8):575-580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/8866384/pubmed" id="8866384" target="_blank">8866384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7982254">
<a name="7982254"></a>Geckler RW. A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract. <i>Clin Ther</i>. 1994;16(4):662-672.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/7982254/pubmed" id="7982254" target="_blank">7982254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18197724">
<a name="18197724"></a>Gilad J, Carmeli Y. Treatment options for multidrug-resistant <i>Acinetobacter</i> species. <i>Drugs</i>. 2008;68(2):165-189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/18197724/pubmed" id="18197724" target="_blank">18197724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31992156">
<a name="31992156"></a>Gkentzi D, Tsintoni A, Christopoulou I, et al. Extensively-drug resistant <i>Acinetobacter baumannii</i> bacteremia in neonates: effective treatment with the combination of colistin and ampicillin/sulbactam. <i>J Chemother</i>. 2020;32(2):103-106. doi:10.1080/1120009X.2020.1716478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/31992156/pubmed" id="31992156" target="_blank">31992156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1416875">
<a name="1416875"></a>Halstenson CE, Wong MO, Herman CS, et al. Effect of concomitant administration of piperacillin on the dispositions on isepamicin and gentamicin in patients with end-stage renal disease. <i>Antimicrob Agents Chemother.</i> 1992;36(9):1832-1836.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/1416875/pubmed" id="1416875" target="_blank">1416875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15865549">
<a name="15865549"></a>Harkless L, Boghossian J, Pollak R, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. <i>Surg Infect (Larchmt)</i>. 2005;6(1):27-40. doi:10.1089/sur.2005.6.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/15865549/pubmed" id="15865549" target="_blank">15865549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23710070">
<a name="23710070"></a>Housman ST, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant <i>Acinetobacter baumannii</i>. <i>J Antimicrob Chemother</i>. 2013;68(10):2296-2304. doi:10.1093/jac/dkt197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/23710070/pubmed" id="23710070" target="_blank">23710070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11213849">
<a name="11213849"></a>Jellison TK, McKinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of <i>Acinetobacter baumannii</i> bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. <i>Pharmacotherapy</i>. 2001;21(2):142-148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/11213849/pubmed" id="11213849" target="_blank">11213849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4345622">
<a name="4345622"></a>Jusko WJ, Lewis GP, Schmitt GW. Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects. <i>Clin Pharmacol Ther</i>. 1973;14(1):90-99. doi:10.1002/cpt197314190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/4345622/pubmed" id="4345622" target="_blank">4345622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521441">
<a name="27521441"></a>Kalil AC, Metersky ML, Klompas M, et al. Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):575-582.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/27521441/pubmed" id="27521441" target="_blank">27521441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanafani.2019">
<a name="Kanafani.2019"></a>Kanafani ZA, Kanj SS. Acinetobacter infection: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 14, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8249199">
<a name="8249199"></a>Kanra G, Seçmeer G, Ozen H, Ceyhan M, Ecevit Z. Comparative therapeutic results of penicillin plus chloramphenicol versus ampicillin plus sulbactam in childhood meningococcemia. <i>Turk J Pediatr</i>. 1993;35(2):87-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/8249199/pubmed" id="8249199" target="_blank">8249199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klompas.2021">
<a name="Klompas.2021"></a>Klompas M. Aspiration pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2677956">
<a name="2677956"></a>Kulhanjian J, Dunphy MG, Hamstra S, et al. Randomized comparative study of ampicillin/sulbactam vs ceftriaxone for treatment of soft tissue and skeletal infections in children. <i>Pediatr Infect Dis J.</i> 1989;8(9):605-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/2677956/pubmed" id="2677956" target="_blank">2677956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18708550">
<a name="18708550"></a>Lam MF, Tang BS, Tse KC, Chan TM, Lai KN. Ampicillin-sulbactam and amikacin used as second-line antibiotics for patients with culture-negative peritonitis. <i>Perit Dial Int</i>. 2008;28(5):540-542.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/18708550/pubmed" id="18708550" target="_blank">18708550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf</i>. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12507838">
<a name="12507838"></a>Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe nosocomial infections with imipenem-resistant <i>Acinetobacter baumannii</i> treated with ampicillin/sulbactam. <i>Int J Antimicrob Agents</i>. 2003;21(1):58-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/12507838/pubmed" id="12507838" target="_blank">12507838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27282851">
<a name="27282851"></a>Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment [published correction appears in <i>Perit Dial Int</i>. 2018;38(4):313]. <i>Perit Dial Int</i>. 2016;36(5):481-508. doi:10.3747/pdi.2016.00078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/27282851/pubmed" id="27282851" target="_blank">27282851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20628102">
<a name="20628102"></a>Li PK, Szeto CC, Piraino B, et al; International Society for Peritoneal Dialysis. Peritoneal dialysis-related infections recommendations: 2010 update [published correction appears in <i>Perit Dial Int</i>. 2011;31(5):512]. <i>Perit Dial Int</i>. 2010;30(4):393-423. doi:10.3747/pdi.2010.00049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/20628102/pubmed" id="20628102" target="_blank">20628102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis.</i> 2012;54(12):e132-e173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22223613">
<a name="22223613"></a>Lorenzen JM, Broll M, Kaever V, et al. Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis. <i>Clin J Am Soc Nephrol</i>. 2012;7(3):385-390. doi:10.2215/CJN.05690611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/22223613/pubmed" id="22223613" target="_blank">22223613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1612532">
<a name="1612532"></a>Maberry MC, Trimmer KJ, Bawdon RE, Sobhi S, Dax JB, Gilstrap LC 3rd. Antibiotic concentration in maternal blood, cord blood and placental tissue in women with chorioamnionitis. <i>Gynecol Obstet Invest</i>. 1992;33(3):185-186. doi:10.1159/000294878<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/1612532/pubmed" id="1612532" target="_blank">1612532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23904004">
<a name="23904004"></a>Majcher-Peszynska J, Loebermann M, Klammt S, et al. CAPNETZ Study Group. Ampicillin/sulbactam in elderly patients with community-acquired pneumonia. <i>Infection</i>. 2014;42(1):79-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/23904004/pubmed" id="23904004" target="_blank">23904004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29531445">
<a name="29531445"></a>Makris D, Petinaki E, Tsolaki V, et al. Colistin versus colistin combined with ampicillin-sulbactam for multiresistant <i>Acinetobacter baumannii</i> ventilator-associated pneumonia treatment: an open-label prospective study. <i>Indian J Crit Care Med</i>. 2018;22(2):67-77. doi:10.4103/ijccm.IJCCM_302_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/29531445/pubmed" id="29531445" target="_blank">29531445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987068">
<a name="29987068"></a>Mancini A, Todd L. Inconsistencies in ISPD peritonitis recommendations: 2016 update on prevention and treatment and the ISPD catheter-related infection recommendations: 2017 update. <i>Perit Dial Int</i>. 2018;38(4):309-310. doi:10.3747/pdi.2018.00026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/29987068/pubmed" id="29987068" target="_blank">29987068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mancino.2019">
<a name="Mancino.2019"></a>Mancino AT, Lalani T. Wound infection following repair of abdominal wall hernia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19297276">
<a name="19297276"></a>Manzoni P, Esposito S, Gallo E, et al. Switch therapy in full-term neonates with presumed or proven bacterial infection. <i>J Chemother.</i> 2009;21(1):68-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/19297276/pubmed" id="19297276" target="_blank">19297276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society (SIS) revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2009;49(1):1-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1759832">
<a name="1759832"></a>Meyers BR, Wilkinson P, Mendelson MH, et al. Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers. <i>Antimicrob Agents Chemother. </i>1991;35(10):2098-2101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/1759832/pubmed" id="1759832" target="_blank">1759832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moehring.2019">
<a name="Moehring.2019"></a>Moehring R, Anderson DJ. Gram-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 12, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31011353">
<a name="31011353"></a>Mosaed R, Haghighi M, Kouchak M, et al. Interim study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin/sulbactam infusion in treatment of ventilator-associated pneumonia due to multidrug resistant <i>Acinetobacter</i>. <i>Iran J Pharm Res</i>. 2018;17(suppl 2):206-213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/31011353/pubmed" id="31011353" target="_blank">31011353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol</i>. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Murray.2019">
<a name="Murray.2019"></a>Murray BE. Treatment of enterococcal infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 14, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10223940">
<a name="10223940"></a>Nahata MC, Vashi VI, Swanson RN, Messig MA, Chung M. Pharmacokinetics of ampicillin and sulbactam in pediatric patients. <i>Antimicrob Agents Chemother.</i> 1999;43(5):1225-1229. doi:10.1128/AAC.43.5.1225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/10223940/pubmed" id="10223940" target="_blank">10223940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2613605">
<a name="2613605"></a>Rho SP, Jones A, Woo M, et al. Single dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young subjects. <i>J Antimicrob Chemother. </i>1989;24(4):573-580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/2613605/pubmed" id="2613605" target="_blank">2613605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3026015">
<a name="3026015"></a>Rodríguez WJ, Khan WN, Puig J, et al. Sulbactam/ampicillin vs. chloramphenicol/ampicillin for the treatment of meningitis in infants and children. <i>Rev Infect Dis</i>. 1986;8(suppl 5):S620-S629. doi:10.1093/clinids/8.supplement_5.s620<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/3026015/pubmed" id="3026015" target="_blank">3026015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rossoff.1995">
<a name="Rossoff.1995"></a>Rossoff LJ, Hilton E, Smith C, Isenberg HD, Simme MM. Intravenous ampicillin/sulbactam versus cefuroxime axetil in the treatment of patients hospitalized with community-acquired lower respiratory tract infections. <i>Curr Ther Res</i>. 1995;56(9):852-862.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28708801">
<a name="28708801"></a>Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, et al. Bone and joint infections. <i>Pediatr Infect Dis J</i>. 2017;36(8):788-799. doi:10.1097/INF.0000000000001635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/28708801/pubmed" id="28708801" target="_blank">28708801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12767844">
<a name="12767844"></a>Smolyakov R, Borer A, Riesenberg K, et al. Nosocomial multi-drug resistant <i>Acinetobacter baumannii</i> bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. <i>J Hosp Infect</i>. 2003;54(1):32-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/12767844/pubmed" id="12767844" target="_blank">12767844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2010;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi: 10.1093/cid/ciu444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3025999">
<a name="3025999"></a>Sutton AM, Turner TL, Cockburn F, et al. Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn. <i>Rev Infect Dis.</i> 1986;8(suppl 5):518-522.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/3025999/pubmed" id="3025999" target="_blank">3025999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Syriopoulou.1986">
<a name="Syriopoulou.1986"></a>Syriopoulou V, Bitsi M, Theodoridis C, et al. Clinical Efficacy of Sulbactam/ampicillin in pediatric infections caused by ampicillin-resistant or penicillin-resistant organisms. <i>Rev Infect Dis.</i> 1986;8(suppl 5):630-633.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987069">
<a name="29987069"></a>Szeto CC, Li PK. Concerns regarding inconsistencies within and between ISPD recommendations for peritonitis and catheter-related infections-in reply. <i>Perit Dial Int</i>. 2018;38(4):311-312. doi:10.3747/pdi.2018.00046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/29987069/pubmed" id="29987069" target="_blank">29987069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34864936">
<a name="34864936"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America (IDSA) Guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant <i>Acinetobacter baumannii</i>, and <i>Stenotrophomonas maltophilia</i> infections. <i>Clin Infect Dis</i>. 2022;74(12):2089-2114. doi:10.1093/cid/ciab1013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/34864936/pubmed" id="34864936" target="_blank">34864936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tita2019">
<a name="Tita2019"></a>Tita ATN. Intraamniotic infections (clinical chorioamnionitis). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis</i>. 2005;41(8):1159-1166. doi:10.1086/444500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284. doi:10.1086/425368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Unasyn.1">
<a name="Unasyn.1"></a>Unasyn (ampicillin sodium and sulbactam sodium) [prescribing information]. New York, NY: Roerig; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Unasyn.2">
<a name="Unasyn.2"></a>Unasyn (ampicillin sodium and sulbactam sodium) [prescribing information]. New York, NY: Roerig; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.2019">
<a name="Weintrob.2019"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/26042815/pubmed" id="26042815" target="_blank">26042815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6309731">
<a name="6309731"></a>Wright N, Wise R. The elimination of sulbactam alone and combined with ampicillin in patients with renal dysfunction. <i>J Antimicrob Chemother</i>. 1983;11(6):583-587. doi:10.1093/jac/11.6.583<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/6309731/pubmed" id="6309731" target="_blank">6309731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7489869">
<a name="7489869"></a>Wynn RL, Bergman SA. Antibiotics and their use in the treatment of orofacial infections, part I and part II. <i>Gen Dent.</i> 1994;42(5):398-402, 498-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/7489869/pubmed" id="7489869" target="_blank">7489869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus fourteen days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial [published online December 11, 2018]. <i>Clin Infect Dis</i>. doi:10.1093/cid/ciy1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27496018">
<a name="27496018"></a>Ye JJ, Lin HS, Yeh CF, et al. Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant <i>Acinetobacter calcoaceticus-Acinetobacter baumannii</i> complex. <i>BMC Infect Dis</i>. 2016;16:374. doi:10.1186/s12879-016-1717-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/27496018/pubmed" id="27496018" target="_blank">27496018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24796218">
<a name="24796218"></a>Yokoyama Y, Matsumoto K, Ikawa K, et al. Pharmacokinetic/pharmacodynamic evaluation of sulbactam against <i>Acinetobacter baumannii</i> in in vitro and murine thigh and lung infection models. <i>Int J Antimicrob Agents.</i> 2014;43(6):547-552. doi:10.1016/j.ijantimicag.2014.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/24796218/pubmed" id="24796218" target="_blank">24796218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25638291">
<a name="25638291"></a>Yokoyama Y, Matsumoto K, Ikawa K, Watanabe E, Morikawa N, Takeda Y. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for <i>Acinetobacter baumannii</i> infections. <i>J Infect Chemother.</i> 2015;21(4):284-289. doi:10.1016/j.jiac.2014.12.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/25638291/pubmed" id="25638291" target="_blank">25638291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24263165">
<a name="24263165"></a>Zalts R, Neuberger A, Hussein K, et al. Treatment of carbapenem-resistant <i>Acinetobacter baumannii</i> ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam. <i>Am J Ther</i>. 2016;23(1):e78-e85. doi:10.1097/MJT.0b013e3182a32df3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ampicillin-and-sulbactam-pediatric-drug-information/abstract-text/24263165/pubmed" id="24263165" target="_blank">24263165</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12695 Version 316.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
